Ensysce Biosciences, Inc. (ENSC) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 16 institutional investors hold a position in Ensysce Biosciences, Inc. (NASDAQ:ENSC).

• Institutional ownership in Ensysce Biosciences edged up to 28.7% in December 2025, compared to 19.9% in September 2025.
• The company experienced a 71.60% quarterly change in institutional shares held, alongside an increase of 60.00% in total owners annually.
• A review of institutional activity for Ensysce Biosciences shows 11 of 16 filers increasing their positions, while 1 reduced their stake, and 4 remained unchanged.
• This class of investors increased its holdings in Ensysce Biosciences to 490.62K shares for the 13F-cycle ending December 2025, up by 204.71K shares quarter on quarter, and up 349.80K shares year over year.
• As of December 31, 2025, ADAGE CAPITAL PARTNERS GP, L.L.C. held Ensysce Biosciences's largest shareholding position with over 149.71K shares, representing 8.76% of total outstanding shares.
• Among the most significant buyers of Ensysce Biosciences during December 2025 were ADAGE CAPITAL PARTNERS GP, L.L.C. (75.00K), DRW Securities, LLC (29.34K), HRT FINANCIAL LP (24.49K), Financial Plan, Inc. (24.00K), TWO SIGMA SECURITIES, LLC (21.61K).
• Leading sellers of Ensysce Biosciences stock in December 2025 included UBS Group AG (700).
• The top 10 institutional holders of Ensysce Biosciences for the quarter ending December 2025 included ADAGE CAPITAL PARTNERS GP, L.L.C. (149.71K), DRW Securities, LLC (98.48K), PERCEPTIVE ADVISORS LLC (86.67K), VANGUARD GROUP INC (36.71K), HRT FINANCIAL LP (24.49K), Financial Plan, Inc. (24.00K), GEODE CAPITAL MANAGEMENT, LLC (22.09K), TWO SIGMA SECURITIES, LLC (21.61K), Williams & Novak, LLC (17.85K), Tower Research Capital LLC (TRC) (5.32K).